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Objective. Photodynamic therapy (PDT) is an effective method for Candida spp. inactivation in vitro and in vivo, but
as yet, no clinical trial has been conducted. This report describes 5 cases of denture stomatitis (DS) treated with PDT.
Study design. Five subjects with clinical and microbiologic diagnosis of DS were submitted to 6 sessions of PDT 3
times a week for 15 days. In each session, patients’ dentures and palates were sprayed with 500 mg/L Photogem, and,
after 30 minutes of incubation, irradiated by light-emitting diode light source at 455 nm (37.5 and 122 J/cm2,
respectively). Cultures of Candida spp. from dentures and palates and standard photographs of the palates were taken
at baseline (day 0), at the end of the treatment (day 15), and at follow-up time intervals (days 30 and 60).
Results. Four patients showed clinical resolution of DS (no inflammation) after PDT sessions, and only 1 subject
demonstrated reduction in palatal inflammation. Recurrence of DS was observed in 2 patients during the follow-up
period.
Conclusions. PDT appears to be an alternative treatment for DS. (Oral Surg Oral Med Oral Pathol Oral Radiol Endod
2011;112:602-608)Denture stomatitis (DS) is an inflammatory lesion of
the palatal mucosa under complete or partial removable
dentures, which may affect up to 65% of denture wear-
ers.1 According to Newton,2 DS may be classified as
localized simple inflammation (type I), generalized
simple inflammation (type II), or inflammatory papil-
lary hyperplasia (type III). Although the etiology of DS
appears to be multifactorial, the presence of Candida
spp. in denture biofilm is considered to be an important
factor in the development of this infection.3 Candida
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602albicans is the most prevalent and virulent species
found in DS, but other species have been shown to
cause infection, with C. glabrata, C. dubliniensis, C.
parapsilosis, C. krusei, and C. tropicalis being the most
commonly described.4 The emergence of non-albicans
species is significant, because they are frequently resis-
tant to commonly used antifungal agents.5,6
Treatment of DS includes good oral hygiene, denture
cleaning procedures, topical or systemic antifungal
agents, discontinuation of nocturnal denture wearing
habit, and eventually denture replacement.7,8 Although
antifungal agents, such as nystatin and fluconazole,
commonly used to treat DS are effective in alleviating
the clinical signs and symptoms of Candida infection,
the recurrence of infection after treatment has fre-
quently been reported.9,10 Moreover, the widespread
use of antifungal agents has resulted in the development
of resistant species.11,12
Therefore, it is necessary to develop alternative ther-
apies for treating DS. One potential alternative is pho-
todynamic therapy (PDT), which combines a photosen-
sitizing agent and an appropriate wavelength of light in
the presence of oxygen producing cytotoxic reactive
species.13,14 Although several in vitro investigations
have demonstrated the photoinactivation of Candida
spp.,15-20 including resistant strains,21 in vivo studies
ide vie
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effective in reducing C. albicans counts in a murine
model of oral candidosis when a porphyrin was asso-
ciated with light from a light-emitting diode (LED).24
Nonetheless, the effect of PDT against DS is still not
known. The present report describes 5 cases of DS
treated with PDT for 15 days and follow-up of each
patient at the time intervals of 30 and 60 days.
SUBJECTS AND METHODS
Five edentulous denture-wearing patients with clini-
cal signs of DS who attended the Araraquara Dental
School for prosthetic treatment were followed. This
study was approved by the Ethics Committee of the
Araraquara Dental School, São Paulo State University,
and each subject signed an informed consent form. The
guidelines of the Helsinki Declaration were followed.
DS was classified according to the criteria proposed by
Newton.2
Diagnosis of Candida infection and recovery of
Candida spp.
For each patient, recovery of Candida spp. was per-
formed by rubbing oral swabs along the palatal mucosa
and the tissue surface of the upper denture. Each swab
was placed into a test tube containing 5 mL 0.9% sterile
saline solution and vortexed for 1 minute to suspend the
organisms from the swab. An aliquot of 50 L from
this suspension was spread plated on Chromagar Can-
dida (Probac do Brasil Produtos Bacteriológicos, São
Paulo, Brazil) and incubated at 30°C for 5 days. Serial
10-fold dilutions from 100 to 103 were plated onto
Sabouraud Dextrose Agar (SDA; Acumedia Manufac-
tures, Baltimore, MD) with 5 g/mL chloramphenicol.
SDA plates were incubated at 37°C for 48 hours. Col-
onies on SDA were quantified using a digital colony
Fig. 1. LED device used to illuminate the dentures. A, Outscounter (CP 600 Plus; Phoenix Ind. Com. Equipamen-tos Científicos, Araraquara, Brazil) and the number of
colony-forming units per milliliter (cfu/mL) deter-
mined. Swabs were collected before treatment (day
0), at the end of the treatment (day 15), and at the
follow-up time intervals of days 30 and 60). Colonies
on Chromagar Candida were presumptively identified
by colony color and submitted to biochemical tests to
confirm all identifications. For this, 1 colony of each
color type on Chromagar Candida was transfered onto
fresh SDA for purity. After 48 hours at 37°C, yeast
isolates were identified using the following biochemi-
cal tests: carbohydrate assimilation pattern using the
ID32C system (Biomérieux, Marcy-L’etoile, France)
and morphologic characteristics produced on corn meal
agar with Tween-80. Only colonies identified as Can-
dida spp. were considered.
Photosensitizer and light sources
The photosensitizer (PS) used in this study was a
hematoporphyrin derivative produced in Moscow (Pho-
togem; Photogem, Moscow, Russia). Solutions of 500
mg/L Photogem were prepared by dissolving the pow-
der in sterile saline solution and were immediately kept
in the dark until the moment before use (pH 6.6).
Two LED devices (LXHL-PR09 and Luxeon III
Emitter; Lumileds Lighting, San Jose, CA) were de-
signed by the Instituto de Física de São Carlos (Physics
Institute, University of São Paulo, São Carlos, Brazil).
They covered the wavelength range from 440 to 460
nm, with maximum emission at 455 nm (royal blue).
One device, used to illuminate the dentures, was com-
posed of 24 LEDs uniformly distributed throughout the
device, resulting in a light intensity of 24 mW/cm2, and
3 air coolers to prevent the denture from heating (Fig.
1). The other device, designed to irradiate the patients’
palates, was composed of 10 LEDs uniformly distrib-
w, B, Inside view.uted on a circular platform with a power output of 260
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mW/cm2, with a distance of 2 cm from the platform
inside the mouth to the deepest area of the palate.
Joined to this platform, a semiconducting chip known
as Peltier was used to dissipate the heat generated by
the LED light. This chip and an air cooler were used to
prevent the device from heating (Fig. 2). For illumina-
tion, the platform remained in the patient’s mouth with
the LED facing toward the palate.
PDT and clinical procedures
Each subject was instructed to brush their dentures
with coconut soap followed by toothpaste after every
meal and before going to sleep. Each patient received a
toothbrush at the beginning of the treatment. They also
received instructions to immerse the dentures in filtered
water overnight. During the 15-day duration of the
treatment and follow-up period (days 30 and 60) time
intervals, each subject was repeatedly given these in-
structions. Every patient had his/her maxillary denture
and palate individually submitted to PDT. The denture
was sprayed with PS, placed in a transparent plastic
bag, and left in the dark for 30 minutes (preirradiation
time [PIT]). For illumination, the denture was placed
inside the LED device and irradiated for 26 minutes
(37.5 J/cm2). The palate was also sprayed with PS and
illuminated after 30 minutes’ PIT. For palate irradia-
tion, the other LED device was handled by the inves-
tigator: The platform with LEDs was placed in the
patient’s mouth and the palate illuminated for 20 min-
utes (122 J/cm2). PDT was performed 3 times a week
for 15 days (6 sessions) in each patient. To document
the clinical response to the treatment, standard photo-
Fig. 2. LED device used to illuminate the patients’ palates.
view.graphs of the palate of all patients were taken beforetreatment (day 0), at the end of the treatment (day 15),
and at the follow-up time intervals (30 and 60 days).
RESULTS
The cfu/mL values recovered from dentures and pal-
ate of each subject before (day 0) and after (day 15)
treatment and at the follow-up time intervals (days 30
and 60) are presented in Table I. During clinical ses-
sions, no patients complained of discomfort, pain or
other symptoms. Only subjects who attended all ses-
sions were considered in this survey. Species of Can-
dida identified during these periods are described in
Table II.
Patient 1
This patient, a 65-year-old European woman, was a
nonsmoker and had taken antihypertensive, diuretic,
and antiinflammatory medications. She had worn her
denture for 6 years continuously, without removing it
for sleeping. Her palate showed DS type II on day 0,
and after PDT sessions (day 15) clinical resolution of
DS (no inflammation) was achieved. On days 30 and 60
after treatment (follow-up period), DS was classified as
0 (healthy mucosa) and I, respectively.
Patient 2
This patient, a 56-year-old European woman, was a
smoker and had used antihypertensive medication. She
had worn her denture for 11 years, without removing it
for sleeping. On day 0, DS was classified as type II, and
after treatment (day 15) petechiae were still present in
view (L, LEDs; P, Peltier chip; AC, air coolers). B, LateralA, Topthe palatal mucosa (type I). At the follow-up period
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verified, and DS was classified as type I and II on days
30 and 60, respectively.
Patient 3
This patient, an 80-year-old European man, was a
nonsmoker and had taken anticoagulant, diuretic, and
digitalis medications. He had worn his denture for 2
years continuously, and DS was classified as type II on
day 0. After PDT sessions (day 15), clinical resolution
of inflammation was observed. However, at the fol-
low-up time interval, recurrence of DS was noted (type
I and II on days 30 and 60, respectively; Fig. 3).
Patient 4
This patient, a 57-year-old European woman, was a
Table I. Cfu/mL values of Candida spp. recovered
from dentures and palate of each patient before (day 0)
and after (day 15) treatment and at follow-up time
intervals (days 30 and 60)
Day 0 Day 15 Day 30 Day 60
Patient 1
D 5.24  104 4.72  103 1.28  104 5.60  104
P 4  10 0 0 0
Patient 2
D 4.64  103 1.4  103 2.00  104 5.04  103
P 4 10 0 4  10 0
Patient 3
D 1.15  105 1.72  104 8.16  104 1.12  104
P 1.2  102 0 4 10 8  10
Patient 4
D 7.6  104 8  10 3.4  105 3.28  105
P 4 10 0 2.68  103 2.00  102
Patient 5
D 7.68  104 0 4.08  105 0
P 4 10 0 0 0
D, Denture; P, palate.
Table II. Species of Candida identified from denture
and palate of each patient before (day 0) and after (day
15) treatment and at follow-up time intervals (days 30
and 60)
Day 0 Day 15 Day 30 Day 60
Patient 1 C. albicans C. albicans C. albicans C. albicans
Patient 2 C. albicans C. albicans C. albicans C. albicans
Patient 3 C. albicans C. albicans C. albicans C. albicans
C. glabrata C. glabrata C. glabrata
Patient 4 C. albicans C. albicans C. albicans C. albicans
C. glabrata C. glabrata C. glabrata
C. tropicalis
Patient 5 C. albicans — C. albicans —nonsmoker and had used antihypertensive medication.She had worn her denture for 15 years continuously. On
her palate, DS type II was observed on day 0. After
treatment (day 15) and at the follow-up time intervals
(days 30 and 60), clinical resolution of palatal inflam-
mation had been achieved.
Patient 5
This patient, a 67-year-old European man, was a
nonsmoker and had taken antihypertensive and antico-
agulant medications. He had worn his denture for 7
years, and on day 0 DS was classified as type II. On day
15 after treatment and at the follow-up time intervals
(days 30 and 60), clinical resolution of palatal inflam-
mation was observed.
DISCUSSION
Dentures produce ecologic changes in the oral mu-
cosa that facilitate the proliferation and the colonization
of microorganisms, especially yeast. Therefore, DS is a
common lesion in denture wearers. Because frequent
recurrence of infection25,26 and the development of
antifungal resistance11,12 caused by antifungal agents
have been observed, alternative therapies for DS are
required. PDT is an effective method for Candida in-
activation in vitro and in vivo,13-24 but no clinical trial
has as yet been carried out with regard to oral Candida
infection. The present report describes 5 DS patients
treated with PDT and the follow-up of each subject.
Cultures of denture and palate of all subjects were
positive for Candida species before the treatment.
Moreover, all patients showed DS type II at baseline
(day 0) and improvement of the palatal inflammation at
the end of the treatment period (day 15). Most patients
showed clinical resolution of DS after PDT sessions,
and only 1 subject (patient 2) demonstrated a reduction
in the palatal inflammation. Concurrently, reduction of
cfu/mL values were also observed after treatment (day
15) compared with baseline (day 0). The encouraging
data observed in these 5 patients suggest that PDT may
be an alternative treatment for DS. Compared with
antifungal agents, PDT appears to be a promising
method of treatment. The production of free radicals
and other reactive oxygen species, such as singlet ox-
ygen, by PDT leads to cellular damage, membrane
lysis, and protein inactivation.13,14 Notably, the mech-
anism of PDT inactivation of fungi is completely dif-
ferent from that of antifungal agents. Although most
antifungal agents inhibit the biosynthesis of ergosterol, the
main sterol in the membranes of fungi,27 the reactive
oxygen species yielded by PDT promote perforation of
the cell wall and membrane, thereby permitting the PS to
translocate into the cell. Once inside the cell, oxidizing
species generated by light excitation induce photodamage
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development of resistance to PDT seems to be unlikely.
In addition to the PDT sessions performed, patients’
compliance with the denture and oral care instructions
they were given may have contributed to achieving
improvement of DS. Although denture and oral hygiene
alone are not sufficient to treat DS,26,28,29 these proce-
dures are essential to maintain a low level of microor-
ganisms on dentures. In addition, application of the
intraoral light may affect patient compliance with the
treatment. Furthermore, in patient 2, the poorer re-
sponse to the treatment could be attributed to smoking,
which is considered to be a risk factor for DS.30,31
During the follow-up period, patients 4 and 5 showed
the best response to the treatment, with no inflamma-
tion verified until day 60. Subjects 2 and 3 developed
recurrence of the initial inflammation (DS type II) on
day 60. Recurrence of DS is often reported,9,25,32 be-
cause the tissue surface of the acrylic resin denture acts
as a reservoir that harbors microorganisms33,34 and is
therefore a potential source of reinfection of patients. In
the present investigation, although no growth of Can-
dida spp. from the palate was observed after treatment,
most of the patients showed growth of Candida spp.
from the denture on day 15 (Table I). When dentures
Fig. 3. Palate of patient 3. A, denture stomatitis (DS) type II
30); D, DS type II (follow-up, day 60).are very old, the indication would be to provide newdentures as adjunctive therapy for complete resolution
of DS.7,35 In the present report, most of the patients had
worn the same denture for 5 years. Although the age
of a denture is related to DS,31,36 patient 3 had been
wearing his denture for only 2 years. Therefore, other
predisposing factors should be considered when treat-
ing DS.
Advancing age is also a risk factor for DS in the
elderly, because cell-mediated immunity, which pro-
vides protection against candidal infection declines
with age.37 According to Ryu et al.,38 some oral envi-
ronmental factors, such as unstimulated salivary flow
rate and age of subjects, are associated with higher
numbers of microbes in the saliva of complete denture
wearers. Those authors suggest that a reduction in the
salivary flow rate with aging induces an increase in
concentration of microbes in saliva. Another predispos-
ing factor associated with DS is medication use. Four
patients were taking antihypertensive medications
which induce xerostomia. Therefore, although an im-
provement in palatal inflammation was verified after
the treatment (day 15), the recurrence that occurred
during the follow-up period may be associated with
these predisposing factors to DS. Because DS is a
); B, no inflammation (day 15); C, DS type I (follow-up, day(day 0multifactorial disease, a suitable treatment should con-
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infection.
In the present report, although improvement of pal-
atal inflammation and reduction of cfu/mL values were
verified after PDT, Candida spp. were recovered after
treatment in most of the patients (Table II). This was an
expected finding, because Candida spp. are normally
isolated from oral mucosa, mainly from dentures, even
in denture wearers without DS.39
In summary, in 4 patients, clinical resolution of DS
was achieved after 6 sessions of PDT, and improve-
ment was observed in 1 patient. These data suggest that
PDT may be an alternative treatment for DS. However,
because only type II DS patients were followed in this
investigation, it is uncertain what treatment response
might be seen in more severe cases. As an alternative
treatment approach, 6 sessions of 20 minutes each for
palatal PDT may be not clinically feasible. Neverthe-
less, this is a preliminary clinical study, and improve-
ments of the PDT parameters are necessary for further
investigations aiming at clinical applications. More-
over, recurrence of DS occurred in 3 of the 5 cases by
30 days, indicating a short-term effect of the therapy.
Longer treatment or other therapeutic regimens (for
example, treatment every 2 weeks) could be assessed in
future investigations. Other types and concentrations of
PS and light source could also be evaluated to achieve
complete inactivation of Candida spp. in vivo and to
properly implement such therapy in the context of a
dental setting.
As other limitations of this study, only 5 cases were
followed, and the majority of them (3 of 5) showed
recurrence of DS. Furthermore, investigators were not
blinded to the therapy, no control treatment was pro-
vided, and there were no objective criteria to discrim-
inate case resolution, improvement, and regression
(only clinical observation of palatal inflammation).
Randomized clinical trials that overcome these limita-
tions should be conducted to evaluate the potential of
PDT in inactivating Candida spp. on dentures and the
oral mucosa, as well as the correlation between clinical
and microbiological data.
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